Clinical Trials Logo
  1. Home
  2. Advanced Tumors
  3. NCT05799183

A SHR-1210 BE Study on Healthy Subjects

Advanced Tumors Clinical Trial

Official title:
A Bioequivalence Study of SHR-1210 in Healthy Subjects

Clinical Trial Summary

The purpose of this study is to assess the bioequivalence of SHR-1210 before and after process changes.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05799183
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact Shaorong Li, Ph.D.
Phone +86-180-0162-4511
Email shaorong.li@hengrui.com
Status Recruiting
Phase Phase 1
Start date July 4, 2023
Completion date November 25, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06245122 - A Study of CS23546 in Subjects With Advanced Tumors Phase 1
Not yet recruiting NCT06314087 - iTAPVR Study - Phase II Randomized Study Phase 2
Recruiting NCT05390528 - A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma Phase 1/Phase 2
Completed NCT02419417 - Study of BMS-986158 in Subjects With Select Advanced Cancers Phase 1/Phase 2
Completed NCT04808453 - Phase I Study of CPI-300 in Patients With Advanced Tumors Phase 1
Recruiting NCT05429008 - A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm Phase 1
Terminated NCT04198818 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors Phase 1/Phase 2
Not yet recruiting NCT05213767 - Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors Phase 1
Not yet recruiting NCT04151810 - Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05068856 - A Study of HRS2543 in Patients With Advanced Tumors Phase 1
Completed NCT03781362 - Study of CPI-100 in Patients With Advanced Tumors Phase 1
Recruiting NCT03908814 - Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors Phase 1
Recruiting NCT05061628 - The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor Phase 1
Recruiting NCT05867771 - A Study of PM1022 in Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT03444714 - Phase I Study of RiMO-301 With Radiation in Advanced Tumors Phase 1